King of Prussia, PA · Founded 2013 · Privately Held (backing)
Operator of a bio-pharmaceutical firm intended to develop gene therapy for people with advanced coronary artery disease. XyloCor Therapeutics is based in King of Prussia, PA and was founded in 2013. It was valued at $130 million at its later-stage round in Jan 2025, the last priced event on record. It has raised $122 million across 3 recorded rounds; the latest was a $4 million seed round in Jan 2021.
PMV mark · valuation
$130.0M
Oct 2026
Priced at
its later-stage round
Jan 2025
Total raised
$122.0M
Last round
Seed Round
Jan 2021
Cap table — not yet on record
XyloCor Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of XyloCor Therapeutics with a free account
·Watch XyloCor Therapeutics: the Monday email on marks, rounds and moves
Where does XyloCor Therapeutics's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across XyloCor Therapeutics's 3 recorded funding rounds.
